Paper Details

  1. Home
  2. Paper Details

Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.

Author: AlonsoM C, AvellaA, BeltránM, BorrásJ, BoschF X, OjedaB, ViladiuP

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 117 postmenopausal women with advanced breast cancer compared three chemotherapy regimens: CMF, CMF plus tamoxifen (TMX), and CMF plus medroxyprogesterone (MAP). CMF plus TMX and CMF plus MAP had higher overall response rates than CMF alone, but there was no difference in complete response rates. After treatment failure, all patients received a second regimen (Adriamycin, vincristine, and either TMX or MAP). Response rates to the second regimen were similar across groups. Patients who responded to both regimens had longer survival compared to those who did not respond or only responded to one regimen. Overall survival was not significantly different between the initial treatment groups. These findings suggest that adding tamoxifen or medroxyprogesterone to CMF may increase response rates, but overall survival may be more dependent on the patient's response to treatment rather than the specific regimen used.
Paper Details　
Original Abstract of the Article :
One hundred seventeen postmenopausal advanced breast cancer patients previously untreated with chemotherapy were randomized to receive: cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), CMF and tamoxifen (TMX), and CMF and medroxyprogesterone (MAP). Treatments B and C induced a greater propo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/1097-0142(19851215)56:12<2745::aid-cncr2820561204>3.0.co;2-g

データ提供：米国国立医学図書館（NLM）

Breast Cancer Treatment: Chemotherapy vs. Chemotherapy Plus Hormonotherapy

The field of [oncology] is constantly seeking new and improved treatments for cancer. This research compares the effectiveness of chemotherapy alone versus chemotherapy combined with hormonotherapy in postmenopausal patients with advanced breast cancer. The researchers conducted a randomized trial with 117 patients, assigning them to receive either cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), CMF plus tamoxifen (TMX), or CMF plus medroxyprogesterone (MAP). The study found that both CMF plus TMX and CMF plus MAP induced a greater proportion of responses compared to CMF alone. However, no significant differences were observed in survival between the treatment groups. This research provides valuable insights into the potential benefits and limitations of combining hormonotherapy with chemotherapy in the treatment of advanced breast cancer.

Navigating Breast Cancer Treatment Options

This research highlights the potential benefits of combining hormonotherapy with chemotherapy in treating advanced breast cancer. While the study did not show significant differences in survival between treatment groups, it did demonstrate a higher response rate for patients receiving hormonotherapy in addition to chemotherapy. These findings emphasize the importance of considering individual patient factors and tailoring treatment strategies to maximize effectiveness.

A Camel's Perspective on Cancer Treatment

As a camel, I know that navigating a challenging journey requires a combination of strength and resilience. This research reminds me that there are multiple paths to consider in treating cancer. It's important to find the right combination of therapies to maximize the chances of success, just as a camel chooses the best path through the desert.

Dr. Camel's Conclusion

This study provides valuable insights into the potential benefits of combining hormonotherapy with chemotherapy in treating advanced breast cancer. While further research is needed to fully understand the optimal strategies for combining these therapies, the study's findings suggest that hormonotherapy may enhance the effectiveness of chemotherapy in some patients. The importance of individualizing treatment approaches based on patient characteristics is underscored, highlighting the need for a personalized approach to cancer care.

Date :
  1. Date Completed 1985-12-19
  2. Date Revised 2019-06-19
Further Info :

Pubmed ID

3902200

DOI: Digital Object Identifier

10.1002/1097-0142(19851215)56:12<2745::aid-cncr2820561204>3.0.co;2-g

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.